Akebia Therapeutics (AKBA) stock

Market cap $178MShares as of Jul 31

$0.64

+13.57%

As of Monday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score AKBA. It is priced too low for a fair Quality Score.

Healthcare · Biotech

Next2027“…for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; initial data expected in 2027”Trial data · SEC filing · Aug 5

Follow AKBA's trial news. Pro members can get an alert when Akebia Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AKBA files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,191 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for AKBA

Next step the company has named

2027“…continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; initial data expected in 2027”Trial data · SEC filing · Aug 5

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Praliciguat in Participants With Focal Segmental GlomerulosclerosisPhase 2 · Recruiting · 60 people · main data estimated Jun 2027 · NCT07268638

2 more trials, 1 with data due this year, 42 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3, filed Sep 3, 2024)
At-the-market share sales program (S-3, filed Sep 3, 2024)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CFO Erik Ostrowski sold 56,019 shares on Jun 29, under a planned sale. 7 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when John Butler buys or sells

For Pro members: every trade, and John Butler’s 6 filings and quotes.

Get an alert when AKBA files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

AKBA's latest filings

A notice about its exchange listing8-K, filed Oct 23
An insider's trade or awardForm 4, filed Aug 10
Quarterly report10-Q, filed Aug 5

23 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why AKBA isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. AKBA trades at $0.64. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.